1,720,976 research outputs found
Cervical Intraepithelial Neoplasia (CIN) in HIV-Infected Women
No full textBackground: to determine the effect of HIV infection on cervical intraepithelial neoplasia. Methods: retrospective study. Results: the sensitivity and specificity of Papanicolaou tests (PAP smear) were 94% and 80%. Patients with a normal Pap smear had higher CD4+ cell count compared to patients with squamous intraepithelial lesions but the difference was not statistically significant (Mann-Whitney test). The distribution of cervical dysplasia was similar regardless of antiretroviral therapy (χP test). 22% of surgically treated women had persistent or recurrent disease. Conclusions: lower CD4+ cell counts are not predictive of the presence of cervical dysplasia. All HIV-infected women, independently from their immunological and clinical conditions, need regular PAP smears with appropriate follow- up for abnormal results
Reductive Surgery and Ovarian Function and in the Human-Can Reductive Ovarian Surgery in Reproductive Age Negatively Influence Fertility and Age at Onset of Menopause?
No full textPotential clinical and economic impact of cross-protection induced by HPV-vaccines in the context of the Italian Regions
No full textScreening e trattamento della displasia cervicale intraepiteliale (CIN) nelle donne HIV-positive
No full textVaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study.
No full textBackground. In the non-hysterectomized postmenopausal woman undergoing estrogen replacement therapy, the co-administration of a progestogen is mandatory to counteract the estrogenic proliferative effect on the endometrium. Metabolic and tissue effects of the various progestins vary with dosage and route of administration. This study was performed to evaluate the effects of selected progestins on the lipidic profile and endometrial morphology. Methods. This is a prospective randomised study including 60 post-menopausal women undergoing hormonal replacement therapy (HRT). All patients received transdermic ethinil-estradiol in a continuous schedule. The utilized progestogens were: medroxyprogesterone acetate (MPA) 10 mg p.o. 12 days/month, transdermic nor-ethisterone acetate (NETA) 0.25 mg integrated in the ethinil-estradiol patches for the last two weeks of each cycle, micronized progesterone (MP) 100 mg transvaginally 12 days/month. Results. None of the tested protocols significantly altered the lipidic profile of this group of patients. We noticed different effects on the estrogen stimulated endometrium elicited by the different progestinic regimens. While the cyclic administration of oral MPA or transdermic NETA more frequently resulted in endometrial atrophy, the trans-vaginal administration of MP more often induced (p<0.005 at sixmonth and p <0.001 after 1 year) a functionallike secretive endometrium. Conclusions. Micronized progesterone, cyclically administered in the form of a vaginal cream, offers an acceptable and effective alternative for women on continuous HRT wishing to maintain their monthly cycle
Overview of the benefitsand potential issues of the nonavalent HPV vaccine
Full text linkHPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined.
Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9vHPV or the quadrivalent HPV (4vHPV) vaccine. The 9vHPV vaccine was shown to have potential benefits as compared with 4vHPV, increasing the overall estimated rate of prevention to 90% for cervical cancer and up to 80% for precancerous cervical lesions. For all other HPV-related
pre-invasive and invasive lesions, 9vHPV showed potentially greater disease reduction, depending on the anatomic region examined. Thus, the 9vHPV vaccine
shows clinical potential for the prevention of HPV-related diseases in both sexes.
Future adoption of 9vHPV will depend on factors including market price, cost-effectiveness data, use of a two-dose schedule, and safety and efficacy monitoring in real-life programs
Cytological analysis of the distension fluid used during diagnostic office hysteroscopies in patients with suspected endometrial pathology.
No full textObjective: Evaluation of the feasibility and usefulness of cytological analysis of the distension fluid used during diagnostic office hysteroscopy in patients with suspected endometrial pathology. Methods: In 243 consecutive patients undergoing diagnostic hysteroscopy for suspected endometrial pathology a few milliliters of the distension medium used for uterine visualization were collected and sent for cytological analysis. Findings of these "endometrial washings" were compared to visual hysteroscopic impression, endometrial biopsy and uterine histology - when available. Results: Endometrial washings were considered adequate in 227 patients (93.4%). In 12 cases (5.3%) atypical cells were detected: all of these presented either atypical complex hyperplasia or endometrial cancer at the final histological evaluation of the uterus. Four of the 16 (25%) patients diagnosed with endometrial cancer or atypical complex hyperplasia at the final histopathological analysis of the uterus had inadequate washings. No patient with cancer or atypical hyperplasia had negative cytology. Conclusions: Collection and analysis of the distension fluid is feasible and, when positive, has a remarkable value in the diagnosis of endometrial cancer and its precursors
- …
